Changes in the Intestinal Microbiome due to Faecal Bacteriotherapy in Patients with Chronic Active Ulcerative Colitis

Not Applicable

• Conditions: fecal bacteriotherapy; K51; Ulcerative colitis

• Registration Number: DRKS00003824
• Lead Sponsor: Klinische Abteilung für GastroenterologieMedizinische Universität Graz

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2012-05-07
• Study Completion: 2012-08-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting stopped after recruiting started
• Sex: All
• Target Recruitment: 6

Inclusion Criteria

Patient: chronic active UC with indication to total colectomy, age >18 and <80, informed consent.
Donor: infomed consent

Exclusion Criteria

Patient: oral anticoagulation, coagulopathy, pregnancy.
Donor: any severe disease (infection, malignancy, autoimmune idsease), any kind of diarrhoea, GI infections or any intestinal disease, antibiotic therapy within the last 6 month.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary endpoint is a sustained reduction of at least 2 points in the MAYO score. Time points of clinical visitation performed by the principal investigator incl. MAYO score, blood tests and endoscopy are day 3,10, 30 and 90.

Secondary Outcome Measures

Name	Time	Method
Secondary endpoint is a sustained chance of intestinal microbiota in patients with chronic activity of UC due to fecal bacteriotherapy.